Who Should Be Tested for Alpha-1 Antitrypsin Deficiency

Every adult with COPD, emphysema, or persistent airflow obstruction that does not fully reverse with a bronchodilator should be tested for alpha-1 antitrypsin deficiency at least once. The same applies to anyone with unexplained chronic liver disease, certain forms of bronchiectasis, or a close blood relative who already carries the diagnosis. This is not a niche recommendation reserved for young patients or lifelong nonsmokers. Guidelines from the COPD Foundation and other respiratory bodies call for broad, one-time testing because the condition is common enough, and consequential enough, to justify looking, and a single blood test usually settles the question.

Why the guidelines cast such a wide net

Alpha-1 antitrypsin (AAT) is a protein made in the liver that shields lung tissue from enzymes released during inflammation. When a person inherits two deficient copies of the SERPINA1 gene, most often the ZZ genotype, blood levels fall and the lungs lose a key defense, which can drive emphysema decades earlier than smoking alone would. The same misfolded Z protein can accumulate inside liver cells, which is why unexplained liver disease at any age is itself a reason to test. The COPD Foundation's adult guideline gives a strong recommendation to test everyone with COPD regardless of age or ethnicity, and to test patients with unexplained chronic liver disease, necrotizing panniculitis, granulomatosis with polyangiitis, or unexplained bronchiectasis. Major respiratory bodies, going back to a 1997 World Health Organization recommendation, have urged that every patient with COPD have an AAT level checked at least once.

The reasoning is population math. Severe ZZ deficiency affects on the order of 1 in 3,500 people in the United States, roughly 100,000 individuals, which makes it more common than several conditions clinicians screen for routinely, yet the large majority of cases are never identified. Testing only the "classic" patient, the young nonsmoker with lower-lobe emphysema, misses most of them, because a deficient person who also smokes looks clinically identical to ordinary COPD. Casting a wide net is what turns a rare-seeming diagnosis into a findable one.

Serum level versus genotype: what each test measures

Two different tests answer two different questions, and the distinction explains why one number can mislead.

A serum AAT level measures how much of the protein is circulating. It is inexpensive and widely available, but it carries a real limitation: AAT is an acute-phase reactant, so its level rises during infection or inflammation and can drift into a falsely reassuring range. The COPD Foundation guideline notes that the spread of serum levels within any single genotype is wide enough that different genotypes overlap, so a level on its own cannot reliably confirm or exclude the diagnosis.

Genotyping asks a sharper question: which alleles did the person inherit? Testing for at least the S and Z alleles is the recommended first line, because those two variants account for the great majority of disease-causing cases. In practice, many laboratories now pair a serum level with targeted genotyping from the same sample, often a finger-stick dried blood spot. When results are ambiguous or a rare or null allele is suspected, testing moves on to expanded genotyping, protein phenotyping, or sequencing of the SERPINA1 gene, which is the approach guidelines reserve for cases of high clinical suspicion.

Why a level alone falls short for families

Once a person is diagnosed, their first-degree relatives become candidates for testing and genetic counseling. Here the guideline is explicit that measuring an AAT level alone is not adequate, because a normal-looking level can hide a carrier state or a deficient genotype. Family testing is meant to characterize the actual genetics rather than the circulating amount alone, so relatives get an answer they can act on.

Why so many cases stay hidden

Despite decades of clear recommendations, fewer than 15 percent of affected people in the United States have been identified, and those who are eventually diagnosed often wait years after their first symptoms, seeing several physicians before anyone orders the test. In one series, close to half of patients had seen at least three physicians before the diagnosis was made. A few forces drive that gap. Breathlessness and cough get attributed to smoking or asthma and treated as such. The blood test is skipped because the obstruction already seems to have an explanation. And because the recommendation is for a single lifetime test rather than a repeating one, a busy visit can quietly assume someone else already checked.

One threshold is concrete enough to name. A serum AAT concentration below roughly 11 micromoles per liter (about 0.57 grams per liter) marks the severe-deficiency range where lung risk concentrates, and it is the level the Canadian Thoracic Society's guideline uses in its conditional recommendation to consider augmentation therapy for selected nonsmoking or former-smoking patients with a deficiency genotype and emphysema. Whether or not augmentation is pursued, knowing the genotype reshapes counseling on smoking, occupational exposures, monitoring, and family screening.

The practical takeaway

The obstacle to diagnosis is rarely the test itself, which is cheap, fast, and increasingly offered as a mail-in kit. The obstacle is remembering to order it. For any adult with fixed airflow obstruction, the evidence supports checking once, combining a serum level with genotyping rather than trusting a level in isolation, and extending testing to first-degree relatives when a case is found. This article is educational and is not a substitute for individual medical advice.